Clinical Trial

Odronextamab in Low Tumor Volume Advanced FL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab. The name of the study drug in this research study is: -Odronextamab (a type of monoclonal antibody)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2026-03-12
Trial Details
NCT Number NCT07128641
Lead Sponsor Gottfried von Keudell, MD PhD
Collaborators: Regeneron Pharmaceuticals
Conditions Follicular Lymphoma, Lymphoma
Enrollment 35 participants
Start Date 2025-09-08
Primary Completion 2027-01-02 (estimated)
Study Completion 2028-01-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-13